Radioterapia personalizada: cáncer de mama 2015. El paradigma de la adaptación bio-tecnológica
23 Jun 2015
Radioterapia personalizada: cáncer de mama 2015. El paradigma de la adaptación bio-tecnológica
Breast Cancer in Latin America
Chemoresistance and residual disease promoted by DNMT3A R882 in AML
TAT 2016: Targeted anticancer therapies
Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL
EHA 2015 highlights
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
Biomarkers for childhood relapsed acute lymphoblastic leukaemia
Are CML patients being treated to the correct standard?
Exciting new developments in proton therapy treatments
PDL1 expression in thymic tumours
Exciting update on the Repurposing Drugs in Oncology (ReDO) project